R. Duarte

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Lung Cancer in Never-Smokers : Epidemiological , Clinical , and Survival Patterns based on Gender

R. Duarte, M. Zamboni, A. Monteiro, 2019 .

Lung Cancer in Never-Smoker Subjects: Epidemiological, Clinical and Survival Patterns based on Gender

R. Duarte, M. Zamboni, A. Monteiro, 2019 .

Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients.

M. Carvalho, Magno Junqueira, G. Domont, 2005, Journal of experimental therapeutics & oncology.

Molecular markers in lung cancer: prognostic role and relationship to smoking.

R. Duarte, M. E. Paschoal, 2006, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients.

R. Luiz, R. Duarte, M. E. Paschoal, 2008, Lung cancer.

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country

R. Rosell, A. Cardona, O. Arrieta, 2023, Cancer control : journal of the Moffitt Cancer Center.

Screening for mutations in Colombian metastatic non-small cell lung cancer (NSCLC) patients (ONCOLGroup).

A. Cardona, A. Jiménez, R. Duarte, 2011, Journal of Clinical Oncology.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

J. Esteve, A. Aventín, S. Brunet, 2012, Leukemia research.

Mucinous adenocarcinoma of the urachus: a practical overview of a broad differential diagnosis: case report

R. Duarte, R. Guevara, A. Balaguera, 2023, International Journal of Surgical Oncology.